These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 8168104

  • 1. Antitumor x anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases.
    Penna C, Dean PA, Nelson H.
    Cancer Res; 1994 May 15; 54(10):2738-43. PubMed ID: 8168104
    [Abstract] [Full Text] [Related]

  • 2. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
    Chapoval AI, Nelson H, Thibault C.
    J Immunol; 1995 Aug 01; 155(3):1296-303. PubMed ID: 7636196
    [Abstract] [Full Text] [Related]

  • 3. Bifunctional antibody retargeting in vivo-activated T lymphocytes: simplifying clinical application.
    Chapoval AI, Nelson H, Thibault C, Penna C, Dean P.
    J Hematother; 1995 Dec 01; 4(6):571-7. PubMed ID: 8846018
    [Abstract] [Full Text] [Related]

  • 4. Depletion of activated Vbeta8+ T cells disrupts bispecific antibody directed antitumor immunity.
    McConnell EJ, McLemore EC, Talac R, Joshi L, Nelson H.
    J Surg Res; 2004 Nov 01; 122(1):103-12. PubMed ID: 15522322
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pulmonary metastases neutralization and tumor rejection by in vivo administration of beta glucan and bispecific antibody.
    Penna C, Dean PA, Nelson H.
    Int J Cancer; 1996 Jan 26; 65(3):377-82. PubMed ID: 8575861
    [Abstract] [Full Text] [Related]

  • 7. [Chimeric T cell receptor N29gamma redirect T lymphocytes response specific to p185HER2 in A murine model of metastatic breast cancer].
    Li SP, Urban FA, Macgregor JN, Hughes DP, McDonagh KT.
    Ai Zheng; 2004 Nov 26; 23(11 Suppl):1370-5. PubMed ID: 15566639
    [Abstract] [Full Text] [Related]

  • 8. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
    Cesson V, Stirnemann K, Robert B, Luescher I, Filleron T, Corradin G, Mach JP, Donda A.
    Clin Cancer Res; 2006 Dec 15; 12(24):7422-30. PubMed ID: 17189415
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In vivo tumor immunotherapy by a bacterial superantigen.
    Ochi A, Migita K, Xu J, Siminovitch K.
    J Immunol; 1993 Sep 15; 151(6):3180-6. PubMed ID: 8376773
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model.
    De Jonge J, Heirman C, de Veerman M, Van Meirvenne S, Moser M, Leo O, Thielemans K.
    J Immunol; 1998 Aug 01; 161(3):1454-61. PubMed ID: 9686611
    [Abstract] [Full Text] [Related]

  • 13. CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen.
    Kahn M, Sugawara H, McGowan P, Okuno K, Nagoya S, Hellström KE, Hellström I, Greenberg P.
    J Immunol; 1991 May 01; 146(9):3235-41. PubMed ID: 1707934
    [Abstract] [Full Text] [Related]

  • 14. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
    Mazzoni A, Mezzanzanica D, Jung G, Wolf H, Colnaghi MI, Canevari S.
    Cancer Res; 1996 Dec 01; 56(23):5443-9. PubMed ID: 8968099
    [Abstract] [Full Text] [Related]

  • 15. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
    Shu S, Krinock RA, Matsumura T, Sussman JJ, Fox BA, Chang AE, Terman DS.
    J Immunol; 1994 Feb 01; 152(3):1277-88. PubMed ID: 8301131
    [Abstract] [Full Text] [Related]

  • 16. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O, Russello O, Leenen C, Diehl V, Bohlen H, Berthold F.
    Med Pediatr Oncol; 2001 Jan 01; 36(1):185-9. PubMed ID: 11464879
    [Abstract] [Full Text] [Related]

  • 17. Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice.
    Garrido MA, Valdayo MJ, Winkler DF, Titus JA, Hecht TT, Perez P, Segal DM, Wunderlich JR.
    Cancer Res; 1990 Jul 15; 50(14):4227-32. PubMed ID: 2142014
    [Abstract] [Full Text] [Related]

  • 18. Comparison of cellular immunotherapies and anti-CD3 in the treatment of MCA-38-LD experimental hepatic metastases in C57BL/6 mice.
    Gallinger S, Hoskin DW, Mullen JB, Wong AH, Roder JC.
    Cancer Res; 1990 Apr 15; 50(8):2476-80. PubMed ID: 2138507
    [Abstract] [Full Text] [Related]

  • 19. Augmentation of antitumor immunity with bacterial superantigen, staphylococcal enterotoxin B-bound tumor cells.
    Shimizu M, Yamamoto A, Nakano H, Matsuzawa A.
    Cancer Res; 1996 Aug 15; 56(16):3731-6. PubMed ID: 8706016
    [Abstract] [Full Text] [Related]

  • 20. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A, Schleer H, Gierschner D, Wetterauer U, Elsässer-Beile U.
    Anticancer Res; 2000 Aug 15; 20(3A):1551-5. PubMed ID: 10928069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.